Archived Facts

Posts Tagged ‘arena’

Arena Pharmaceuticals Inc. said Thursday it took a smaller loss in the second quarter after it received a large payment following the approval of its obesity drug Belviq.

Related Posts:

Shares of Arena Pharmaceuticals Inc. fell in premarket trading Monday after the Food and Drug Administration rejected the company’s application for the potential weight-loss drug.

View full post on All News, Video and Posts related to SECTOR: Health Care

Related Posts:

Arena Pharmaceuticals Inc. on Saturday said the Food and Drug Administration has rejected the company’s application for lorcaserin, one of three drugs seeking to become the first new FDA-approved prescription weight loss drug in more than a decade.

View full post on All News, Video and Posts related to SECTOR: Health Care

Related Posts:

Shares of Arena Pharmaceuticals Inc. sank Monday on analyst questions about troublesome data seen in animals tested with the company’s weight-loss drug lorcaserin.

View full post on All News, Video and Posts related to SECTOR: Health Care

Related Posts:

Shares of Arena Pharmaceuticals Inc. tumbled in premarket trading Friday, a day after a Food and Drug Administration panel rejected its weight loss pill lorcaserin.

View full post on All News, Video and Posts related to SECTOR: Health Care

Related Posts:

Arena Pharmaceuticals Inc faces tough questions and possibly lawsuits from angry investors after it failed to disclose that its experimental weight-loss drug caused cancer in rats.

View full post on All News, Video and Posts related to SECTOR: Health Care

Related Posts:

NOT SO SAFE: Federal health officials delivered a surprisingly negative review of an experimental weight loss drug from Arena Pharmaceuticals which was thought to offer a safer alternative to older drugs. Reviewers questioned the drug’s heart and psychiatric side effects.

See more here:
Summary Box: FDA takes dim view of new diet drug

Related Posts:

Analyst Research on Arena Pharmaceuticals (NASDAQ: ARNA) and Vivus (NASDAQ: VVUS) — Biotech Overview
TORONTO–(Marketwire – 09/09/10) – www.BedfordReport.com has released its latest newsletter providing in-depth analyst research on some of the hottest names in the Biotech industry including Arena Pharmaceuticals, Inc. (NASDAQ: ARNA – News ) and Vivus, Inc. (NASDAQ: VVUS – News ). Register for a free membership today at www.bedfordreport.com[[[SHIFTIN …

Read more on Marketwire via Yahoo! Finance

Incoming search terms:

Related Posts:

Shares of Arena Pharmaceuticals Inc. fell Monday after a JPMorgan analyst recommended a cautious stance on the stock, citing the near-term risks compared with the rewards for the obesity drug lorcaserin.

Continue reading here:
Arena shares fall on JPMorgan downgrade

Related Posts:

Shares of Arena Pharmaceuticals continued gaining ground Monday after last week’s negative recommendation against potential competitor Vivus Inc.

View full post on All News, Video and Posts related to SECTOR: Health Care

Related Posts: